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Abstract: Drug administration via the transdermal route is an evolving field that provides 
an alternative to oral and parenteral routes of therapy. Several microneedle (MN) based 
approaches have been developed. Among these, coated MNs (typically where drug is 
deposited on MN tips) are a minimally invasive method to deliver drugs and vaccines 
through the skin. In this review, we describe several processes to coat MNs. These include 
dip coating, gas jet drying, spray coating, electrohydrodynamic atomisation (EHDA) based 
processes and piezoelectric inkjet printing. Examples of process mechanisms, conditions  
and tested formulations are provided. As these processes are independent techniques, 
modifications to facilitate MN coatings are elucidated. In summary, the outcomes and 
potential value for each technique provides opportunities to overcome formulation or 
dosage form limitations. While there are significant developments in solid degradable 
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MNs, coated MNs (through the various techniques described) have potential to be utilized 
in personalized drug delivery via controlled deposition onto MN templates. 
Keywords: microneedles; coatings; drug delivery; coating process; films; particles 
 
1. Introduction 
Transdermal drug delivery (e.g., transdermal patches) offers an attractive alternative to oral and 
parenteral routes of drug administration. These methods have provided significant contributions 
towards pharmaceutical (emerging therapies) applications (e.g., vaccination, skin treatment and for 
controlled release). Such administration routes have a distinct advantage in overcoming the first pass 
effect of the liver, which can prematurely metabolize active drugs [1]. Most transdermal systems are 
inexpensive, non-invasive, are self-administrated and provide sustained release of the active drug (up 
to one week) which improves patient compliance [1,2]. However, transdermal delivery is limited to a 
number of drugs due to the major barrier function of the skin [3]. The skin has three layers: epidermis 
(which is the main physical barrier), dermis and a fat layer. The epidermis of the skin has five separate 
layers: stratum basale (basal or also known as the germinativum cell layer), stratum spinosum (spinous 
or also known as the prickle cell layer), stratum granulosum (granular cell layer), stratum corneum 
(also termed the horny layer) and stratum lucidum (located between the stratum granulosum and stratum 
corneum). Stratum corneum (the superficial layer of the skin) is the most challenging barrier for 
transdermal drug delivery [4,5]. 
Several enhancement approaches have been utilized in order to increase skin permeability, ranging 
from chemical/lipid penetration enhancers to non-cavitation ultrasound, thermal ablation, 
iontophoresis, sonophoresis, microdermabrasion, electroporation, cavitational ultrasound and microneedles 
(MNs) [1,3,6–10]. Although the principles and mechanisms of these approaches are different, these 
methods share the same aim of enhancing the movement of the drug through the stratum corneum, 
either through pore formation or improved diffusive interaction. This facilitates the movement of drug 
molecules towards the blood supply in the skin [8] or the Langerhans cells for vaccine delivery. 
In the last twenty years, MNs have been proposed as pain-free systems (significantly less painful 
than a 26-gauge hypodermic needle) [11] with high potential of transdermal drug delivery (via 
perforated regions of the stratum corneum). This is achieved by avoiding or minimizing underlying 
pain nerve stimulation [5]. MNs have been manufactured in different shapes and sizes from a broad 
range of materials to deliver drugs with variable molecular size and weight [10,12]. MNs present an 
attractive drug delivery approach with the potential for delivering molecules with functional properties 
and also macromolecules [9], e.g., bovine serum albumin [6,8], calcein [13], desmopressin [14], 
parathyroid hormone PTH [15], insulin [16], OVA protein [17] and horseradish peroxidase [18]. 
Vaccines that have been coated onto MNs include hepatitis B antigens [19], inactivated influenza  
virus [20] and virus-like particles (influenza) [21]. 
MNs have the advantages of delivering small quantities of high-potency medication through the 
skin to minimize the pain factor [22] and allowing precise tissue localization for drug delivery [13]. 
Moreover, large active pharmaceutical molecules can be administered without causing pain using MNs 
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as they only puncture the epidermal skin layer [8]. They can also be used for biological analysis (via 
skin blood contact). Due to minimal invasiveness they offer the advantage of fast healing at the 
injection site (local skin area) with low risk of microbial infection [3]. MNs also have the added 
benefit of rapid penetration of drugs directly into the blood circulation system (compared to skin 
diffusive approaches), subsequently avoiding the first pass effect of the liver and the digestive enzymes 
of the gastrointestinal tract [1]. Furthermore, a selection of active and functional molecules (small 
molecules, e.g., calcein, and large molecules, e.g., proteins) and vaccines are well tolerated through 
controlled MN delivery [3]. While this technique is termed pain-free, it is also minimally invasive 
without long-term oedema or erythema. A rapid onset of drug delivery can be accomplished by 
coupling MNs with an electrically controlled micro-pump which can effectively determine the rate of 
drug delivery as compared with other drug delivery approaches [23]. 
The application of MNs is limited due to their size and material properties. MN tips are prone to 
breakage and subsequent embedment within the skin if prepared from materials with poor mechanical 
properties [7,23]. Furthermore, the thickness of the stratum corneum and other skin layers differs 
between specimen and anatomical location. Accordingly, the penetration depth of the drug is variable 
and dosage accuracy is limited. Allergy prone or sensitive skin is also affected by MNs (e.g., material 
type and skin irritation). Improper MN application technique can also lead to skin inflammation by 
increased drug impregnation under the skin [3]. 
This short review focuses on MNs as transdermal drug delivery systems. The review provides an 
overview of the advantages and disadvantages of MN systems. Moreover, examples of different MN 
structures, coating methods and coating formulations are highlighted. Specifically, emerging and 
existing MN coating methods are summarized in a table (Table 1) that details key aspects for these 
developments (e.g., drug, coating materials, processes and main outcomes). 
2. Microneedle Mechanism and Design 
MNs have been developed in ways that enable them to share advantages of both hypodermic 
needles and transdermal patches to deliver drugs through the skin at therapeutically desirable  
quantities [6–10]. The combinatorial design of such MNs has overcome the limitations of the 
hypodermic needles (pain and risk associated) and transdermal patches (limited by the transport barrier 
provided by stratum corneum) [11]. 
MNs are significantly different from hypodermic needles based on their length and the pore size 
they generate (ranging from sub-microns to millimeters). Generally, MN patches or substrates possess 
similar basic design elements such as an ordered array of MNs ranging from a few to a few hundred in 
number. MNs are prepared from various materials and manufactured in a plethora of shapes and  
sizes [6–11]. They were originally micro-fabricated from silicon and later manufactured from metals, 
polymers and ceramics (including glass). 
The design of MNs and the way in which the drug or formulation is incorporated to target the skin 
varies. There are four main MN designs. The first is an array of solid MNs (with no drug) which is 
used to penetrate into the skin, increasing skin permeability for the intended drug (e.g., drug usually 
applied using patch or topical formulation). The second type is degradable MNs, prepared using 
biodegradable polymers (e.g., poly(lactic-co-glycolic acid) (PLGA) polymer). These degrade safely in 
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the skin while providing a sustained release of drug [24,25]. This one-step method has provided 
precise drug dosing with 90% bioavailability [26]. However, low bioavailabilites (32%) have been 
reported for peptide leuprolide acetate (1.2 kDa) which has shown metabolic instability in the  
skin [27]. The third type is injectable hollow MNs which permit the continuous delivery of drug into 
the skin [13]. MNs contain hollow bores which minimize invasiveness and reduce pain typically 
experienced during hypodermic needle drug delivery. Hollow MNs are inserted into the skin, after 
which liquid formulation is actively or passively infused into the injected tissue. The final type is 
coated MNs, in which design (conventionally) metallic MNs are coated with a drug formulation. These 
MNs are ideal for the delivery of potent drugs into the skin after piercing through the stratum  
corneum [3]. For instance, vaccines coated onto MNs can endorse their desired response by interacting 
with the dermal dendritic cells (Langerhans cells) [28,29]. Moreover, high molecular weight molecules 
can be rapidly delivered into the skin, through self-implementation, such as with “Band-Aid”-like 
systems [13]. Coated MNs also possess the advantage of prolonged shelf-life. For example, 98% 
integrity of desmopressin (synthetic peptide hormone) coated onto MNs was maintained after 6 months 
of storage under nitrogen at ambient conditions [14]. In general, the coating process, excipients, 
selected active drug and formulation all have an impact on MN coatings. High drug loading volumes 
with improved strength, protection against moisture and controlled drug release are other factors which 
provide benefits of coated MN systems [13]. It is also imperative to have a coating thickness in the 
micron range which does not occlude the needles or inhibit skin penetration. However, the quantity of 
the drug to be administered using this method is limited to the amount of the drug that can be coated 
onto the tips and shafts of MNs. This is normally less than 1 mg for small MNs arrays [13]. Coated 
MNs retain their mechanical strength; however, their tip sharpness is reduced and this impacts skin 
penetration ability. 
Gill et al., investigated the influence of MN geometry (using MNs with variations in length, 
thickness, width, tip angle and number of MNs on a patch) on pain compared to a 26-gage hypodermal 
needle. All MNs investigated were 5% to 40% less painful than the selected hypodermic needle. The 
thickness, width and tip angle had no significant impact on pain. However, decreasing the number and 
length of the MNs decreased the pain significantly. In addition, increasing the number of MNs 10-fold 
resulted in a two-fold increase in pain (by score). They also concluded that a three-fold increase in MN 
length resulted in a seven-fold increase in pain (by score) [11]. 
3. Microneedle Coating Methods 
Coated MNs are attractive devices for drug delivery through the skin. Previously, MNs were coated 
by immersing patches in a liquid solution for several hours to ensure a full coat onto their surface. 
However, this simple procedure has the drawback of drug wastage and loss, variable coating thickness 
of active onto MNs and thus inaccuracy in drug dosage [13]. Different coating approaches have been 
developed to date, including dip coating, gas-jet drying, spray-coating, EHDA based processes and 
piezoelectric ink-jet printing. These are illustrated in Figure 1. 
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Figure 1. Illustrated examples of techniques used to coat MNs. (a) Dip coating; (b) Gas-jet 
drying; (c) Spray drying; (d) EHDA processes; (e) Ink-jet printing. 
3.1. Dip Coating 
The dip coating process is the simplest procedure to coat MNs. MNs are first dipped into the 
formulation and then withdrawn. This step produces a liquid film on MNs. The liquid layer is then 
allowed to dry to form a solid film coating. The dip coating method has been utilized to deliver 
hydrophilic and hydrophobic drugs. Several biomolecules have been coated onto MNs using this 
technique, e.g., proteins, viruses and DNA, for rapid transdermal delivery [30]. 
Ma and Gill, have reported one of the earliest attempts at coating a hydrophobic drug onto MNs 
using molten dip coating. Lidocaine (MW = 270.8 Da) is a hydrophobic drug which is used as a local 
anesthetic agent. Usually, the administration of lidocaine to the patient is either topically (i.e., cream) 
or parentally (i.e., injection). Here, the molten dip coating process was used to develop uniform 
lidocaine coated MNs for transdermal delivery. Polyethylene glycol (PEG) was used as a hydrophilic 
matrix with a lidocaine base to create the solid dispersion. Drug stability was achieved even at elevated 
temperatures of ~130 °C. The mass fraction of lidocaine in the drug dispersion had an impact on the 
PEG-lidocaine molten solution, as decreasing the mass fraction of lidocaine increased the solution 
viscosity. Compared to the conventional 1 h application of topical cream (0.15 g EMLA®, a 5% 
emulsion of equal quantities of 2.5% lidocaine and 2.5% prilocaine), the in vitro dissolution studies of 
PEG-lidocaine coated MNs in porcine skin demonstrated a significant increase in lidocaine delivery 
within 3 min [31]. 
Human growth hormone (191 amino acids) is a peptide which is important for growth, cell 
regeneration and reproduction in humans. Recombinant human growth hormone (rhGH) was 
successfully dip coated onto titanium MNs for transdermal delivery (200 mg/mL; 20% w/w). rhGH 
MN patches were stable for 6 months at 40 °C. Compared to commercial subcutaneous Norditropin 
injection (rhGH), rhGH coated MNs were found to provide a similar absolute bioavailability. This 
suggests rhGH MN patches have potential to replace rhGH injections in the pharmaceutical market due 
to reduced pain benefits and ease of administration [32]. 
The dip coating method works by submerging MNs into a drug solution and could result in a non-
uniform coating [30]. Surface tension is a dominant feature which prevents uniform MN coatings as 
they are closely spaced [33]. Gill and Prausnitz developed a micron scale dip coating process to 
produce uniformly coated MNs. This process relies on coating MN shafts with a thick layer of coating 
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and not the base substrate using a highly viscose formulation to decrease surface tension. MNs of 
different geometries and configurations (single MNs, in-plane rows of MNs, and out-of-plane arrays of 
MNs) were laser cut from stainless steel sheets using an infrared laser followed by electropolishing. 
This dip coating design used dip holes with similar dimensions of MNs rather than a large open 
coating surfaces to avoid rising of the meniscus subsequently masking the base substrate within the 
spaced MNs. MN shafts were coated with very small volumes of formulation, ranging from 10 μL for 
single MNs to 100 μL for 50 MNs (out-of-plane arrays). A variety of biomolecules (3% Vitamin B, 1% 
bovine serum albumin, 0.05% g Wiz™ luciferase plasmid DNA, 0.01% suforhodamine and modified 
vaccinia virus) were utilized with a modified coating solution (1% (w/v) of low viscosity 
carboxymethyl cellulose sodium salt and 0.5% (w/v) Lutrol F-68 NF). Here, MN shafts were coated 
without contaminating the base. Coated materials dissolved (to liquid form) within 20 s in porcine 
cadaver skin with complete delivery into the skin [13]. 
3.2. Gas Jet Drying 
The slow drying process associated with the dip coating approach is limited practically, especially 
for curved MNs. While the drug coating solution is still wet on the MN surface, the solution has 
potential to move (gravitational and low surface tension spreading) and relocate off the MN surface, 
reducing and varying the desired dose. Even the multi-dip coating approach is potentially problematic 
as a thick multi-layer [34] coating (of solution) accumulates and dries at the base substrate. The gas jet 
drying approach was developed by Chen et al., to overcome the addressed problem, especially for  
very small (<90 micron length) and very closely (~20.000 cm−2) spaced MNs. Solid silicon 
microprojections were sputter coated with a thin layer of gold. The whole length of the 
microprojections was coated with a (6–8 µL) solution which possessed ideal surface tension and 
viscosity properties. The coating solution contained methylcellulose (works by increasing the viscosity 
and decreasing the surface tension of the coating solution at the same time), Quil-A (has benefits of 
serving as a surfactant to reduce the surface tension and works as a vaccine immune-stimulatory 
adjuvant) and selected concentrations of model active drugs (vaccines or fluorescent dyes). 
Formulations were applied and were modified using (6–8 m/s) a gas jet. The viscosity of the coated 
layer (5 µm thick) onto the microprojections increased rapidly, allowing the coated material to dry 
rather than relocate on the base substrate. This was followed by a fast gas jet (10 m/s) at an incident 
angle of 20° to remove all excess coating solution. The uniformly dried coating remained intact during 
skin penetration and the model drugs were released in 3 min within wet skin [17]. 
Vaccine delivery using MNs has merits over diffusion (the movement of drug from an area of high 
drug concentration to low concentration) delivery, biolistic MN delivery and electroporation delivery 
approaches. Vaccines comprise large molecular weight actives which has limited their MN based 
deployment. Typically, transdermal delivery favors small drug molecules (<500 Da) to pass through 
the stratum corneum. Chen et al., have improved vaccine delivery efficiency by using gas jet coated 
MNs, by focusing on depositing actives on MN tips rather than whole MNs. This was performed by 
increasing the gas jet incident angle to 70°, removing the patch edge and rotating the patches during 
the coating process to ensure uniformity. The delivery efficiency of vaccines was increased from  
7.3% ± 1.1% to 17.8% ± 1.5% (for incident angle 20°) simply by removing the patch edge. Delivery 
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efficiency increased from 17.8% ± 1.5% (for incident angle 20°) to 32.5% ± 3.9% (for incident angle 
70°) based on the incident angle with continuous rotating of patches [35]. 
3.3. Spray Coating 
The spray coating process is similar to conventional coating approaches (e.g., used for coating 
tablets) to achieve millimetre thicknesses. The micron sized design of MNs (typically ~60 to 700 μm 
in height) requires a coating thickness in and below the micron range (particles size < 280 μm). Spray 
coating of microparticles onto MNs undergoes three steps. Firstly atomization, which is the generation 
of formulated microdroplets from the spray coater. Secondly, the deposition and adherence of droplets 
onto the surface of MNs. Finally, the coalescence of droplets on the substrate to form an intact film  
coating [36]. 
The spray coating process was first developed by McGrath et al. [36]. The configuration of the 
spraying system involved a 0.5 mm spraying nozzle which was connected to a compressed air pump 
and a coating solution. Silicon MNs were secured on the platform stage under the nozzle using double 
sided tape. Using a peristaltic pump or a syringe driver, the coating solution was injected into the 
nozzle for atomisation. Optimization of spray process parameters (e.g., atomization air pressure, gun-
to-surface distance and air cap setting) are necessary for uniform film coating on the MN substrate. 
The film coat formation was highly affected by the coating solutions physio–chemical properties and 
the spray process parameters. Two coating materials were investigated (hydroxypropylmethylcellulose 
(HPMC) and carboxymethylcellulose (CMC)). HPMC was considered as a good film forming polymer 
that readily formed a film coat after optimizing process parameters. 1% w/v CMC solution had a higher 
surface tension than 5% w/v CMC and both HPMC solutions (5% and 12% w/v). Solutions with high 
polymer concentrations (5% w/v CMC, 12% w/v HPMC) demonstrated greater viscosities (compared 
to 1% w/v CMC, 5% w/v HPMC). These parameters adversely affected film-coating coalescence as the 
resulting film had a combination of small patches of coating and large uncoated areas. The addition of 
a surfactant (Tween 80) in the case of CMC solutions was necessary to assist coalescence of the 
sprayed droplets onto the silicon surface [36]. 
Spray coated solid MN patches were also used for transcutaneous delivery of live recombinant 
adenovirus (rADV) and modified vaccinia virus Ankara (MVA) vectors as vaccines. Viruses with 
suitable sugar-based formulations were spray coated in a dry form at the shaft of each silicon MN 
rather than the inter-needle space. A uniform coating pattern with an effective preservation of the 
virus’s activity was successfully delivered into the skin. The potency of recombinant virus vaccine 
coated onto MNs patches to induce antibody response, transcutaneous infection and induced antibody 
(or CD8+ T cell) response was equivalent to the response induced by transdermal injection of the same 
vaccine [37]. 
3.4. EHDA Based Processes 
The electrohydrodynamic atomisation (EHDA) process has been developed to generate near 
uniform micro- and nano-meter scaled architectures in one step. The principle process was described 
by Grace and Marijnissen (1994). Here, atomized droplets are produced by an electrically imposed 
moving liquid (the electrical field generates charge inside droplets) that jet through a capillary nozzle 
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exit and are subsequently collected over a ground electrode positioned below the nozzle tip [38]. The 
liquid used is a polymeric solution, or formulation, containing three main components (a solvent, 
polymer and active drug) and possibly other excipients. This technique has been widely used by 
researchers for various drug delivery therapies e.g., insulin [39], folic acid [40], titanium dioxide 
antimicrobial agent [41], gold used in gene delivery [42] etc. The EHDA system can generate both 
particles (electrospraying) and fibers (electrospinning). 
Using the EHDA process, controlled particle and fibre coating thickness is achievable. Khan et al., 
presented a multi-structural MN coating approach employing EHDA principles. Stainless steel MNs 
(600–900 µm height) were attached to the ground electrode. The coating solution (containing 5 wt % 
of selectable molecular weights of polyvinylpyrrolidone (PVP) dissolved in methanol:ethanol (50:50) 
and fluorescein dye (serving as a potential drug)) was infused into a three needle co-axial device which 
was connected to a high voltage supply. The MNs were coated with particles (100 nm to 3 µm) and 
fibres (400 nm to 1 µm) under controlled processing parameters, flow rate (~5–15 µL/min) and applied 
voltage (6–19 kV) at room temperature. This coating process can assist in advancing transdermal drug  
delivery [34]. This is especially important for sensitive biomolecules such as peptides and  
protein drugs which are stable during EHDA processes but unstable for delivery via oral route of  
administration [34,39,43]. In comparison to dip coating, the electrical spray-coating system (e.g., 
EHDA system) can be optimized to coat MN tips only and avoid coating the base substrate (by using 
surface insulating polymeric masks). 
There are three main types of EHDA processes: single needle (in which the formulation is injected 
into a single nozzle by a single precision syringe pump), coaxial EHDA (this system uses two or more 
immiscible liquids which are fed through separately enveloped nozzles) and multiplexed EHDA 
(liquid formulation fed through a single or coaxial nozzle array). One of the benefits of EHDA using a 
coaxial system is protection of the sensitive drug from direct exposure to the biological environment [44]. 
This is related to the encapsulating architecture of the produced particle/fibres in which the 
biomolecule will be located in the core while the polymer forms the outer layer. Accordingly, the coaxial 
EHDA system is preferred as it can produce therapeutic particles with sustained and controlled release. 
Certain parameters need to be considered when using EHDA process: flow rate, applied voltage and 
the distance between the nozzle and the collecting platform [45]. These factors have a high impact on 
the controlled particle size, size distribution, porosity, shape and surface charge. Applied voltage is the 
most important factor in controlling the jet mode and the size of resulting particles/fibres, as increasing 
the applied voltage will result in smaller particles/fibres [38]. Moreover, as the applied voltage is 
increased significantly the morphology of particles have the potential to transition from spherical to 
elongated (change in aspect ratio). An optimum voltage is determined to overcome the surface tension 
on the initially atomized droplets. Flow rate has a direct relation to the particle size and the size 
distribution of the produced architectures as the size reduces with decreasing flow rate. The distance 
between the tip of the needle and the ground platform has an impact on resulting morphologies. This is 
due to the relaxation time required for solidifying droplets to reach the deposition substrate, which can 
be increased by increasing the distance between the two points [38,46]. 
In addition to processing parameters, material properties also impact resulting particles/fibres as 
they significantly affect the jet stability. The viscosity, surface tension, electrical conductivity and 
density are all major factors to be considered before processing [47]. The most important parameter is 
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the electric conductivity of the vehicle (solvent), as liquid with low electrical conductivity (e.g., 
heptane) cannot be used for single needle EHDA systems. The addition of antistatic additives or their 
coupling with an electrically conductive liquid improves process ability (e.g., through coaxial  
EHDA) [48]. Atomised particle size is directly related to solution viscosity and surface tension, while 
the reverse is true with regard to liquid density [38]. 
3.5. Piezoelectric Inkjet Printing 
The inkjet printing approach is a valuable engineering apparatus that enables controlled distribution 
and accurate arrangement of fine liquid droplets (1–100 picoliters) onto a substrate (e.g., MNs) before 
solidification [49,50]. Unlike the dip coating method, inkjet printing technology requires formulations 
with low viscosity to avoid blockage of the jetting nozzle (which possess small dimensions) for a 
continuous MN coating process [51]. The concept involves dissolving selected excipients in a liquid to 
form an ink. The mechanism of drop formation and ejecting from the nozzle occurs by either (1) 
inducing vibrations on the material by using a voltage supply connected to a piezoelectric transducer 
(piezoelectric inkjet printing), or (2) increasing the temperature of the formulation (to slightly higher 
than its boiling point) which leads to thermal inkjet printing [49,50]. 
Piezoelectric (piezo) inkjet printing technology is the most acknowledged industrial inkjet printing 
process. In this approach, a piezoelectric crystal (ceramic actuator) undergoes distortion by the effect 
of an electric field that creates a pressure pulse in the ink chamber forcing drops to eject from the 
nozzle. The droplet size is correlated with the nozzle dimensions [51]. 
Combination of MNs (as drug delivery systems) with piezoelectric inkjet printing (as precise drug 
coating technology) permits an advanced approach in the pharmaceutical arena. Boehm et al., 
fabricated biodegradable polyglycolic acid MNs coated with voriconazole (antifungal agent) using 
piezoelectric inkjet printing. This system was compared with unmodified and vehicle modified MNs 
against different micro-organisms (Candida albicans, Escherichia coli, Pseudomonas aeruginosa and 
Staphylococcus aureus). Voriconazole-polyglycolic acid MNs showed antifungal activity against 
Candida albicans while other devices were ineffective. The method was identified as a useful 
application of piezoelectric inkjet printing for drug loading onto MNs for poorly soluble 
pharmacological agents [52]. Micronazole (antifungal agent) was also printed onto MNs created from 
Gantrez® AN 169 BF (poly(methyl vinyl ether-co-maleic anhydride)) using piezoelectric inkjet 
printing technology. Dimethyl sulfoxide was used as a solvent to enhance the antifungal drug 
penetration. Miconazole-loaded Gantrez® AN 169 BF MNs exhibited antifungal activity against 
Candida albicans [50]. 
Three anticancer agents with varying solubilities (5-fluororacil (5-FU), curcumin (CRC) and 
cisplatin (CPT)) were utilized for transdermal delivery using MNs. At various drug-polymer ratios, 
anticancer agents with soluplus® coatings (a copolymer used to increase the solubility of water 
insoluble drugs, hence dissolution rates) were uniform, reproducible and printable onto metallic MNs 
using the piezoelectric inkjet printing approach. The release profile depended on drug solubility. 
Hydrophilic 5-FU showed a rapid release profile compared to water insoluble CRC and CPT. 
However, varying antiproliferative action was observed for the three anticancer agents. 
Antiproliferative activity was concentration dependent, and at low concentrations (15 µg/mL) no 
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antiproliferative activity was observed but observation increased with drug dose. This was dependent 
on drug potency as 7% and 9.4% viability was observed for 7 µg/mL (CRC) and 200µg/ml (CPT), 
respectively, sufficient to trigger antiproliferative activity. 5-FU was least potent with 20% cell viability 
at 400 µg/mL [51]. 
Piezoelectric inkjet printing technology was also combined with visible light dynamic mask micro-
stereolithography-micromolding as a new approach of engineering polymeric MNs. Beohm et al., used 
this combination of two prototyping methods to fabricate biodegradable acid Gantrez AN-139 
anhydride copolymer MNs containing quantum dots. Deposition of quantum dots was confirmed in 
deeper layers of the skin (>200 μm depth from surface) after successful penetration into the stratum 
corneum. This valuable combination enables the development of sensors and theranostic devices 
(combination of detecting and drug delivery in one system) [53]. 
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in length, Cone 
Solutions 





Two step process. Includes the application of 
formulation and then drying based on gas-jet 
with variable speeds at specific incident 
angles 
Densely packed MN 
successfully coated using this 
method. Method can be 
considered for large molecules. 
[17] 
Silicon 







Human Influenza Vaccine 
(Fluvax®) 
Film 
As above. MN patches were rotated to 
ensure uniformity. A nitrogen gas-jet  
was used 
An improved approach to 
deliver vaccine to low-resource 
regions with long time 
stability. Tracer was 
incorporated into coating 
[35] 
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Multiple variables can be used for spray 
optimisation.  Coated MNs were dried for 
12 h at the ambient temperature. Factorial 
design used to determine best coating 
formulation 
Various conventional tablet coating 
polymers deployed for coating MNs. 
Multiple variables involved which 
impact spraying time. Surfactant may be 










Sodium salt, Tween 







Process optimised to control direct 
deposition on to MNs. This also required 
careful isolation of viruses during 
deposition. Multiple variables can be used 
for spray optimisation. Coated MNs were 
dried under vacuum (with desiccant) for a 
further 2–24 h 
Uniform coating significantly preserved 
the virus’s activity which was 
successfully delivered into the skin and 
resulted in antibody response equivalent 
to the response induced by transdermal 






500 µm in 
length, 
Flat 
Solutions PVP FLR dye 
Particles and 
Fibres 
Multiple variables in this process. 
Reduced drying time due to non-aqueous 
solvent deployment for formulation. 
Coating thickness variable—dependent 
on deposition time. Ambient condition 
process 
Solution properties used to prepare 
coating formulations are critical to the 









Solutions DMSO MNZ 
Micro-
droplet Film 
MNs were exposed to UV light prior to 
printing with formulation. Ambient 
temperature process. Six layers of printed 
patterns applied. 38 µg of MNZ dose per 
patch prepared 
Printing system presents an opportunity 
for poorly soluble anti-fungal drugs. A 
multi-mode engineering approach is a 



















Plotting of droplets on to MNs at 45°. 
Droplets deposited in continuous jetting 
cycles to increase coating. Process is 
computer controlled to determine 
volumes and real time deposition via 
imaging 
Controlled deposition (of a droplet) 
using a controlled deposition device. 
Piezo-electric jet head used. Droplet size 













Small quantities of formulations loaded 
into printer cartridge. 1 µg of the drug 
onto each MN patch system. Precision 
controlled deposition. Three layers 
deposited 
VNZ-PGA MNs showed antifungal 
activity against Candida albicans. 
Accordingly, this system is ideal for 
poorly soluble pharmacological agents 
[52] 
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MC: Methyl cellulose; HPMC: Hydroxypropylmethylcellulose; CMC: Carboxymethyl cellulose; BSA: Bovine serum albumin; PEG: Polyethylene glycol; PMVE/MA: 
Poly(methyl vinyl ether-co-maleic anhydride; PVP: Polyvinylpyrrolidone; PGA:polyglycolic acid; FITC: fluorescein isothiocyanate; FLR: Flourescein; 14C-OVA: 14-C 
Ovalbumin; OVA: Ovalbumin; VNZ: voriconazole; MNZ: Miconazole; 5-FU: Fluorouracil; rADV: recombinant human adenovirus; rhGH: recombinant human growth 
hormone; MVA: vaccinia virus Ankara; DMSO: dimethyl sulfoxide. 
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4. Conclusions 
Microneedle based delivery of therapeutics is a rapidly evolving area in the pharmaceutical remit, 
and within the approach of microneedle based delivery, several sub-classes exist. Coated MNs offer 
advantages over existing routes of parenteral drug delivery including pain-free and self-administration 
options (when compared to injections). Coated MN systems also possess benefits over other MN types, 
including the ability to pattern MN surfaces and control the dose (based on the coating formulation) in 
a facile manner. They also allow the retention of microstructures within the coated system and allow 
formulation to be located specifically onto MN templates. The coating of MNs can be achieved using 
several techniques, including emerging process such as EHDA technology, printing and gas jet drying. 
In particular, these current advances provide opportunities for developing advanced drug delivery 
systems for personalized and tailored transdermal medicines. 
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